NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

A Randomized, Open-Label, Parallel-group, Multicenter Phase 1/2 Study to Evaluate the Safety and Exploratory Efficacy of NT-101 Topical Ophthalmic Solution in Patients With Wet Age-Related Macular Degeneration (AMD)

Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)

Study Overview

• Status: Completed
• Conditions: Wet AMD; Wet Age Related Macular Degeneration
• Intervention / Treatment: Drug: NT-101 Low Dose; Drug: NT-101 High Dose

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Rosedale, Maryland, United States, 21237
      • Elman Retina Group
  • North Carolina
    • Durham, North Carolina, United States, 27705
      • Duke Eye Center
  • Pennsylvania
    • Erie, Pennsylvania, United States, 16505
      • Erie Retina Research
  • Texas
    • Dallas, Texas, United States, 75231
      • Texas Retina Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Subject who is male or female ≥ 50 years of age at Screening.

2. Choroidal neovascularization (CNV) lesions secondary to AMD that affected the central subfield in the study eye that meets the following criteria at Screening:

   • Total area of CNV (including both classical and occult) comprising > 50% of the total lesion area on FA
   • Leakage covering > 50% of the total lesion area on FA
   • Intraretinal and/or subretinal fluid affecting the central subfield visible on OCT.

   If fluid is not visible due to previous treatment, earlier documented OCT images showing fluid for diagnosing wet AMD can be reviewed to fulfill this criterion.

   • No atrophy or fibrosis involving the center of the fovea.

3. BCVA between 25 and 78 letters, inclusive, in the study eye at Screening using ETDRS testing, with BCVA decrement primarily attributable to wet AMD.

4. Either no previous treatment in the study eye with anti-VEGF therapy (treatment naïve) or previously treated study eye with adequate washout from the baseline visit as defined below:

   • Lucentis (ranibizumab): 30-day washout
   • Avastin (bevacizumab): 30-day washout
   • Eylea (aflibercept): 60-day washout
   • Eylea (aflibercept) high dose 8mg: 90-day washout
   • Vabysmo (faricimab-svoa): 90-day washout

   • Biosimilars

     • Byooviz (ranibizumab-nuna): 30-day washout
     • Cimerli (ranibizumab-eqrn): 30-day washout
5. Demonstrate the ability to instill eye drops (by the subject or caregiver) in the study eye, express willingness to comply with the dosing regimen, and commit to attending all study visits.
6. Understands and voluntarily signs an informed consent form.

7. Female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse, or agree to practice two acceptable methods of contraception throughout the course of the study and 3 months after their last study administration. Acceptable methods of contraception include :

   • hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring),
   • intrauterine device,
   • barrier methods (diaphragm, condom) with spermicide, or
   • surgical sterilization (hysterectomy or tubal ligation).

Exclusion Criteria:

1. Subject who has the following illness or abnormal laboratory test values at

   Screening:

   • Uncontrolled hypertension (systolic > 180 mmHg or diastolic > 100 mmHg) despite optimal medical regimen
   • Uncontrolled diabetes (HbA1c > 12.0%)
   • Total bilirubin > 1.5 × Upper Limit of Normal (ULN)
   • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
   • Prothrombin time (PT) > 1.5 x ULN
   • Hemoglobin (Hb) < 10 g/dL (male); Hb < 9 g/dL (female)
   • Platelets < 100 x 103/μL
   • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
   • Positive results for Human Immunodeficiency Virus (HIV) or Hepatitis B or C viruses
2. Other clinically significant abnormal lab values per Investigator's judgement.
3. Subject who has a medical condition that, in the opinion of the Investigator, would preclude participation in the study (e.g., unstable medical status including psychiatric disorder, cardiovascular disease, poor glycemic control, and significant medical condition including end-stage renal disease and severe liver diseases).
4. History of stroke or myocardial infarction within 6 months prior to Screening.
5. Subject who has had major surgery within 3 months prior to Screening.
6. Pregnant or breastfeeding or intended to become pregnant during the study.
7. Subject with known hypersensitivity to any active substance or excipients of the investigational product, fluorescein, dilating eye drops, or any of the anesthetic and antimicrobial drops.
8. Treatment with investigational therapy or participation in any other type of interventional trial within 30 days before Screening.
9. Subject who has a history of AMD treatment in the study eye with Beovu® (brolucizumab) or photodynamic therapy.
10. CNV in the study eye secondary to other causes or subject who has an ocular condition (other than AMD) that, in the opinion of the Investigator, may limit visual acuity improvement during the course of the study (e.g., ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, multifocal choroiditis, congenital eye malformations, retinal pigment epithelial tear, or posterior uveitis etc.)
11. Media opacities or abnormalities in the study eye that would preclude visualization of the retina.
12. Subject who has a history of retinal detachment or retinal detachment repair surgery in the study eye.
13. Subject who has a history of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to randomization in the study eye.
14. Uncontrolled glaucoma in either eye (IOP > 25 mmHg despite treatment with a standard regimen of antiglaucoma medications), with exceptions allowed at the Investigator's discretion.
15. Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in either eye on Screening.
16. Subject who has a history of vitrectomy in the study eye.
17. Subject who has a history of ocular surgery in the study eye (including cataract extraction, any intraocular surgery, etc.) within 3 months prior to Screening or anticipated within the next 6 months following randomization.
18. Subject who has any history of intraocular inflammation in either eye other than what would be expected in the normal post-operative course following prior routine ocular surgery such as cataract surgery.
19. Subject who has other retinal pathologies in the study eye that would interfere with vision, such as evidence of diabetic macular edema or diabetic retinopathy (defined as more than one microaneurysm).
20. Non-study eye with a BCVA worse than 20 letters at Screening using ETDRS testing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NT-101 Low Dose	Drug: NT-101 Low Dose; Low concentration of NT-101 (0.05 mM)
Experimental: NT-101 High Dose	Drug: NT-101 High Dose; High concentration of NT-101 (0.2 mM)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number and Severity of Treatment-Emergent Adverse Events (TEAEs) up to Week 8	8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in CST in the Study Eye	Measured by: SD-OCT | Unit: Micrometers (µm)	Week 4 compared to baseline
Change in ETDRS BCVA Letter Score in the Study Eye	Unit: Letter Score	Week 4 compared to baseline
Change in IOP in the Study Eye	Unit: Millimeters of Mercury (mmHg)	Week 4 compared to baseline

Collaborators and Investigators

• Sponsor: NexThera Co., Ltd.
• Collaborators: KCRN Research, LLC

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2025
• Primary Completion (Actual): December 15, 2025
• Study Completion (Actual): May 6, 2026

Study Registration Dates

• First Submitted: November 18, 2024
• First Submitted That Met QC Criteria: November 21, 2024
• First Posted (Actual): November 25, 2024

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 17, 2026
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: wet AMD; Age related Macular Degeneration; Eyedrop
• Additional Relevant MeSH Terms: Eye Diseases; Retinal Diseases; Retinal Degeneration; Macular Degeneration
• Other Study ID Numbers: NT101-AMD-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No